KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding: 2017-2025

Historic Shares Outstanding for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $121.7 million.

  • Aquestive Therapeutics' Shares Outstanding rose 33.43% to $121.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 33.43%. This contributed to the annual value of $91.4 million for FY2024, which is 33.39% up from last year.
  • Aquestive Therapeutics' Shares Outstanding amounted to $121.7 million in Q3 2025, which was up 22.45% from $99.4 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Shares Outstanding high stood at $121.7 million for Q3 2025, and its period low was $36.2 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding was $91.1 million (2024), whereas its average is $85.2 million.
  • Data for Aquestive Therapeutics' Shares Outstanding shows a peak YoY soared of 61.79% (in 2024) over the last 5 years.
  • Aquestive Therapeutics' Shares Outstanding (Quarterly) stood at $41.2 million in 2021, then skyrocketed by 32.98% to $54.8 million in 2022, then rose by 25.00% to $68.5 million in 2023, then spiked by 33.39% to $91.4 million in 2024, then spiked by 33.43% to $121.7 million in 2025.
  • Its last three reported values are $121.7 million in Q3 2025, $99.4 million for Q2 2025, and $99.3 million during Q1 2025.